Control of Cyclin D1 and Breast Tumorigenesis by the EglN2 Prolyl Hydroxylase

Cancer Cell

Volumn 16, Issue 5, 2009, Pages 413-424

  Zhang, Qing ^a   Gu, Jinming ^a   Li, Lianjie ^a,d   Liu, Jiayun ^a   Luo, Biao ^b   Cheung, Hiu Wing ^b   Boehm, Jesse S ^b   Ni, Min ^a   Geisen, Christoph ^a   Root, David E ^b   Polyak, Kornelia ^a   Brown, Myles ^a   Richardson, Andrea L ^a,c   Hahn, William C ^a,b   Kaelin Jr , William G ^a,d   Bommi Reddy, Archana ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

CELLCYCLE

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; EGIN2 ENZYME; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CATALYSIS; CELL PROLIFERATION; CONTROLLED STUDY; DROSOPHILA; HUMAN; HUMAN CELL; IN VIVO STUDY; MAMMARY GLAND; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BREAST NEOPLASMS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CYCLIN D1; DIOXYGENASES; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; IMMUNOBLOTTING; MICE; MICE, TRANSGENIC; PROCOLLAGEN-PROLINE DIOXYGENASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 70350507985     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2009.09.029     Document Type: Article

References (52)

1. Appelhoff R.J., Tian Y.M., Raval R.R., Turley H., Harris A.L., Pugh C.W., Ratcliffe P.J., and Gleadle J.M. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J. Biol. Chem. 279 (2004) 38458-38465
2. Aragones J., Schneider M., Van Geyte K., Fraisl P., Dresselaers T., Mazzone M., Dirkx R., Zacchigna S., Lemieux H., Jeoung N.H., et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat. Genet. 40 (2008) 170-180
3. Aravind L., and Koonin E.V. The DNA-repair protein AlkB, EGL-9, and leprecan define new families of 2-oxoglutarate- and iron-dependent dioxygenases. Genome Biol. 2 (2001) research0007
4. Bartkova J., Lukas J., Muller H., Lutzhoft D., Strauss M., and Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer 57 (1994) 353-361
5. Berra E., Benizri E., Ginouves A., Volmat V., Roux D., and Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 22 (2003) 4082-4090
6. Boehm J.S., Hession M.T., Bulmer S.E., and Hahn W.C. Transformation of human and murine fibroblasts without viral oncoproteins. Mol. Cell. Biol. 25 (2005) 6464-6474
7. Bolstad B.M., Irizarry R.A., Astrand M., and Speed T.P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19 (2003) 185-193
8. Boyer S.N., Wazer D.E., and Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56 (1996) 4620-4624
9. Bruegge K., Jelkmann W., and Metzen E. Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases. Curr. Med. Chem. 14 (2007) 1853-1862
10. Brugarolas J., Lei K., Hurley R.L., Manning B.D., Reiling J.H., Hafen E., Witters L.A., Ellisen L.W., and Kaelin Jr. W.G. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18 (2004) 2893-2904
11. Corso S., Migliore C., Ghiso E., De Rosa G., Comoglio P.M., and Giordano S. Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene 27 (2008) 684-693
12. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001) 43-54
13. Frei C., and Edgar B.A. Drosophila cyclin D/Cdk4 requires Hif-1 prolyl hydroxylase to drive cell growth. Dev. Cell 6 (2004) 241-251
14. Geng Y., Whoriskey W., Park M.Y., Bronson R.T., Medema R.H., Li T., Weinberg R.A., and Sicinski P. Rescue of cyclin D1 deficiency by knockin cyclin E. Cell 97 (1999) 767-777
15. Halbert C.L., Demers G.W., and Galloway D.A. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65 (1991) 473-478
16. Hsieh M.M., Linde N.S., Wynter A., Metzger M., Wong C., Langsetmo I., Lin A., Smith R., Rodgers G.P., Donahue R.E., et al. HIF-prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and fetal hemoglobin expression in rhesus macaques. Blood 110 (2007) 2140-2147
17. Kaelin Jr. W.G., and Ratcliffe P.J. Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol. Cell 30 (2008) 393-402
18. Klose R.J., Kallin E.M., and Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat. Rev. Genet. 7 (2006) 715-727
19. Kozar K., Ciemerych M.A., Rebel V.I., Shigematsu H., Zagozdzon A., Sicinska E., Geng Y., Yu Q., Bhattacharya S., Bronson R.T., et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 118 (2004) 477-491
20. Landis M.W., Pawlyk B.S., Li T., Sicinski P., and Hinds P.W. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 9 (2006) 13-22
21. Laughner E., Taghavi P., Chiles K., Mahon P.C., and Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21 (2001) 3995-4004
22. Li Y.M., Zhou B.P., Deng J., Pan Y., Hay N., and Hung M.C. A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res. 65 (2005) 3257-3263
23. Lu X., Lu X., Wang Z.C., Iglehart J.D., Zhang X., and Richardson A.L. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res. Treat. 108 (2008) 191-201
24. Luo B., Cheung H.W., Subramanian A., Sharifnia T., Okamoto M., Yang X., Hinkle G., Boehm J.S., Beroukhim R., Weir B.A., et al. Highly parallel identification of essential genes in cancer cells. Proc. Natl. Acad. Sci. USA 105 (2008) 20380-20385
25. Maxwell P.H., Wiesener M.S., Chang G.-W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
26. Metzen E., Berchner-Pfannschmidt U., Stengel P., Marxsen J.H., Stolze I., Klinger M., Huang W.Q., Wotzlaw C., Hellwig-Burgel T., Jelkmann W., et al. Intracellular localisation of human HIF-1 alpha hydroxylases: Implications for oxygen sensing. J. Cell Sci. 116 (2003) 1319-1326
27. Minamishima Y.A., Moslehi J., Bardeesy N., Cullen D., Bronson R.T., and Kaelin Jr. W.G. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 111 (2008) 3236-3244
28. Minamishima Y.A., Moslehi J., Padera R.F., Bronson R.T., Liao R., and Kaelin Jr. W.G. A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol. Cell Biol. (2009) in press. Published online August 31, 2009. MCB.00331-09v1
29. Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W., Giri D.D., Viale A., Olshen A.B., Gerald W.L., and Massague J. Genes that mediate breast cancer metastasis to lung. Nature 436 (2005) 518-524
30. Moffat J., Grueneberg D.A., Yang X., Kim S.Y., Kloepfer A.M., Hinkle G., Piqani B., Eisenhaure T.M., Luo B., Grenier J.K., et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124 (2006) 1283-1298
31. Mole D.R., Schlemminger I., McNeill L.A., Hewitson K.S., Pugh C.W., Ratcliffe P.J., and Schofield C.J. 2-oxoglutarate analogue inhibitors of HIF prolyl hydroxylase. Bioorg. Med. Chem. Lett. 13 (2003) 2677-2680
32. Nakayama K., Frew I.J., Hagensen M., Skals M., Habelhah H., Bhoumik A., Kadoya T., Erdjument-Bromage H., Tempst P., Frappell P.B., et al. Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell 117 (2004) 941-952
33. Neuman E., Ladha M.H., Lin N., Upton T.M., Miller S.J., DiRenzo J., Pestell R.G., Hinds P.W., Dowdy S.F., Brown M., and Ewen M.E. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol. Cell. Biol. 17 (1997) 5338-5347
34. Ozer A., and Bruick R.K. Non-heme dioxygenases: Cellular sensors and regulators jelly rolled into one?. Nat. Chem. Biol. 3 (2007) 144-153
35. Pollard P.J., Loenarz C., Mole D.R., McDonough M.A., Gleadle J.M., Schofield C.J., and Ratcliffe P.J. Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha. Biochem. J. 416 (2008) 387-394
36. Rantanen K., Pursiheimo J., Hogel H., Himanen V., Metzen E., and Jaakkola P.M. Prolyl hydroxylase PHD3 activates oxygen-dependent protein aggregation. Mol. Biol. Cell 19 (2008) 2231-2240
37. Reiling J.H., and Hafen E. The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev. 18 (2004) 2879-2892
38. Roy P.G., and Thompson A.M. Cyclin D1 and breast cancer. Breast 15 (2006) 718-727
39. Safran M., Kim W.Y., O'Connell F., Flippin L., Gunzler V., Horner J.W., Depinho R.A., and Kaelin Jr. W.G. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production. Proc. Natl. Acad. Sci. USA 103 (2006) 105-110
40. Schlisio S., Kenchappa R.S., Vredeveld L.C., George R.E., Stewart R., Greulich H., Shahriari K., Nguyen N.V., Pigny P., Dahia P.L., et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 22 (2008) 884-893
41. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
42. Seth P., Krop I., Porter D., and Polyak K. Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression). Oncogene 21 (2002) 836-843
43. Sicinski P., Donaher J.L., Parker S.B., Li T., Fazeli A., Gardner H., Haslam S.Z., Bronson R.T., Elledge S.J., and Weinberg R.A. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82 (1995) 621-630
44. Steeg P.S., and Zhou Q. Cyclins and breast cancer. Breast Cancer Res. Treat. 52 (1998) 17-28
45. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., and Mesirov J.P. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005) 15545-15550
46. Takeda K., Ho V.C., Takeda H., Duan L.J., Nagy A., and Fong G.H. Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol. Cell. Biol. 26 (2006) 8336-8346
47. Takeda K., Aguila H.L., Parikh N.S., Li X., Lamothe K., Duan L.J., Takeda H., Lee F.S., and Fong G.H. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 111 (2008) 3229-3235
48. Taylor M.S. Characterization and comparative analysis of the EGLN gene family. Gene 275 (2001) 125-132
49. Tian Y.M., Mole D.R., Ratcliffe P.J., and Gleadle J.M. Characterization of different isoforms of the HIF prolyl hydroxylase PHD1 generated by alternative initiation. Biochem. J. 397 (2006) 179-186
50. Yu Q., Geng Y., and Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 411 (2001) 1017-1021
51. Yu Q., Sicinska E., Geng Y., Ahnstrom M., Zagozdzon A., Kong Y., Gardner H., Kiyokawa H., Harris L.N., Stal O., and Sicinski P. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9 (2006) 23-32
52. Zwijsen R.M., Wientjens E., Klompmaker R., van der Sman J., Bernards R., and Michalides R.J. CDK-independent activation of estrogen receptor by cyclin D1. Cell 88 (1997) 405-415